Focus: CRISPR Therapeutics is a Boston-based biotechnology company focused on CRISPR-Cas9 gene therapy, targeting hematologic malignancies, genetic blood disorders, and autoimmune diseases. The company operates as a mid-cap biotech with a diversified pipeline spanning multiple therapeutic areas.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Stable — net +4 jobs in 30d
7 added, 3 removed. Backfill posture.
Strong platform and lead program catalysts make this a compelling opportunity for gene-therapy specialists willing to tolerate pre-commercial clinical-stage risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for CRISPR Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from CRISPR Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI) The Globe and Mail
Vanguard Group Inc. Reduces Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Vanguard Group Inc. Reduces Stock Position in CRISPR Therapeutics AG $CRSP MarketBeat
8-K Filing: MAXCYTE, INC. (MXCT) (CIK 0001287098) — EX-99.2
EX-99.2
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? - The Motley Fool
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? The Motley Fool
Best CRISPR Gene Editing ETFs for 2026 and How to Invest - The Motley Fool
Best CRISPR Gene Editing ETFs for 2026 and How to Invest The Motley Fool
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference - The Manila Times
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference The Manila Times
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo